Update from ASCO 2019
Update from ASCO 2019
LYMPHOMA CONNECT has summarised highlights of the recent ASCO 2019 meeting LYMPHOMA CONNECT has summarised highlights of the recent ASCO 2019 meetingProf. Paul M Barr
Watch the video and download the slidesProf. Paul M Barr
Haematologist/Oncologist
University of Rochester Medical Center
United States (US)
Paul M. Barr MD is a Professor of Medicine at the University of Rochester Medical Center in Rochester, New York. He received his MD from Northeastern Ohio Medical University. His internal medicine and hematology / oncology training was completed at Case Western Reserve University where he also served as Chief Medical Resident. Joining the University of Rochester lymphoma program in 2010, his primary research focus is on novel drug development for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Current efforts revolve around the development of novel combinations incorporating inhibitors targeting the B cell receptor signaling pathway, supported by the Lymphoma Research Foundation and Hope Foundation. Beyond his individual research interests, he is a strong advocate for oncology clinical research. He serves as the Medical Director of the Clinical Trials Office for the Wilmot Cancer Center overseeing all industry sponsored, cooperative group and investigator initiated studies.
Prof. Paul M Barr has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
| 5 min | 2019
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.